You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
浙江醫藥(600216.SH):蘋果酸奈諾沙星氯化鈉注射液、蘋果酸奈諾沙星膠囊兩款產品進入國家醫保目錄
格隆匯 12-03 16:18

格隆匯12月3日丨浙江醫藥(600216.SH)公佈,2021年12月3日,國家醫保局、人力資源社會保障部發布了《關於印發〈國家基本醫療保險、工傷保險和生育保險藥品目錄(2021年)〉的通知》。經國家醫保局組織專家評審,並通過平等友好協商,浙江醫藥股份有限公司蘋果酸奈諾沙星氯化鈉注射液、蘋果酸奈諾沙星膠囊兩款產品新增或續約進入《國家醫保目錄(2021年)》。

奈諾沙星是一種新型無氟喹諾酮類抗生素,用於治療由肺炎鏈球菌、金黃色葡萄球菌、流感嗜血桿菌、副流感嗜血桿菌、卡他莫拉菌、肺炎克雷伯菌以及肺炎支原體、肺炎衣原體和嗜肺軍團菌所致的成人(≥18歲)社區獲得性肺炎。奈諾沙星區別於其他喹諾酮類藥物的主要特點是喹諾酮母核C6位無氟,降低了氟相關的不良反應。同時C8位甲氧基取代,增強了對革蘭陽性菌的抗菌活性。

Cortellis數據查詢,2020年奈諾沙星全球市場規模為410萬美元,其同類藥物莫西沙星的全球銷售額為7.3億美元。米內數據查詢,2020年奈諾沙星國內銷售額為5610萬人民幣,其同類藥物莫西沙星的國內銷售額為41.5億人民幣。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account